Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05684770

Impact of Remote Care in Patients Diagnosed With Thromboembolic Disease of Low Risk

The goal of this clinical trial is to learn about the feasibility and impact of remote care in patients diagnosed with thromboembolic disease of low risk. The main questions it aims to answer are:

* the evaluation of feasibility of organisation between different healthcare professionals (hospital physicians, primary care physician) at 6 months and 1 year * the evaluation of complication rate, hospitalisation related to thromboembolic disease rate, compliance to treatment rate at 6 months and 1 year Participants will receive indication of treatment according to national recommendations. Additionnally, they will receive for the length of study a 4G tablet in order to fill questionnaires, learn information about their drugs (patient education), have a remote consultation and evaluate treatment compliance.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients identified in the emergency department with a thromboembolic disease, with a deep vein thrombosis or pulmonary embolism with a low risk of mortality according to recommendations
  • affiliated or beneficiary of social protection

Exclusion criteria

  • patient having a severe obstruction syndrome, a thromboembolic disease already under treatment or a suspicion of thrombocytopenia induced by heparin
  • patient with an active hemorrhage or a major risk of hemorrhage, a renal severe failure, comorbidities such as cancer, or the impossibility to organise a consultation or a patient in a non favorable medico-social context
  • patient with a caval thrombosis
  • patient suffering of a disease at hemorrhagic risk or neurosurgery intervention done in the last month or other surgery in the last 15 days prior to inclusion
  • patient with contraindication of direct oral anticoagulants, such as bitherapy with antiplatelet agent, imidazoles, macrolides, antiretroviral treatments or an anti-phospholipid syndrome
  • patient that lives in an area not covered by internet
  • patient that has no primary care physician
  • patient not able to understand the study (language, psychological problem) or not able to read or write
  • patient under legal protection

Treatment and study plan

4G tablet

Other

Participants will receive for the whole period of study a 4G tablet in order to fill questionnaires, learn information about their drugs (patient education), have a remote consultation and evaluate treatment compliance.

Primary outcomes

  1. Number of participants in which the evaluation of medical and patient satisfaction regarding feasibility of organisation assessed by three scales (patient scale, hospital physician scale and primary care physician scale) is satisfactory

    Time frame: 6 months

    Three scales were created for this study :

    • patient scale : difficulty perceived to use the tablet, added value in the use of tablet, improvement of communication with physicians
    • hospital physician scale : global satisfaction (scale from 0 to 10), perception on the follow-up of patient through tablet, improvement of communication with patients and with primary care physician
    • primary care physician scale : global satisfaction (scale from 0 to 10), perception on the follow-up of patient through tablet, improvement of communication with patients and with hospital physician

Secondary outcomes

  1. Number of patients in which the evaluation of medical and patient satisfaction regarding feasibility of organisation assessed by three scales (patient scale, hospital physician scale and primary care physician scale) is satisfactory

    Time frame: 1 year

    Three scales were created for this study :

    • patient scale : difficulty perceived to use the tablet, added value in the use of tablet, improvement of communication with physicians
    • hospital physician scale : global satisfaction (scale from 0 to 10), perception on the follow-up of patient through tablet, improvement of communication with patients and with primary care physician
    • primary care physician scale : global satisfaction (scale from 0 to 10), perception on the follow-up of patient through tablet, improvement of communication with patients and with hospital physician
  2. Evaluation of complication rate related to thromboembolic disease

    Time frame: 6 months and 1 year

  3. Evaluation of hospitalisation rate related to thromboembolic disease

    Time frame: 1 year

  4. Evaluation of treatment compliance

    Time frame: 6 months and 1 year

    This will be evaluated by the communication between the physician and the patient during consultation

Study contacts

Contact information is provided by the study sponsor or research team.

Lydia BEN BEKKOU, ARC

CONTACT

[email protected]

+332 32 33 86 75

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Eure-Seine

Other

Registry information

Official study title

Evaluation of Feasibility and Impact of Remote Care in Patients With Thromboembolic Disease of Low Risk

Acronym: TEVEDOM

Important dates

Study start
2025
Primary completion
2027
Study completion
2028
First posted
Jan 13, 2023
Registry last updated
Sep 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.